Metastases in bones, lymph nodes and lungs are common challenges among oncology patients (e.g. breast cancer, prostate cancer, osteosarcoma) and are the primary cause of death. Efficacious new treatment options are sorely needed. Alpha-particle emitting radionuclides being highly cytotoxic may fulfil this critical need. We study a novel technology with potentially broad therapeutic applications for cancer micrometastases by means of dual targeted alpha particle radiation. The treatment involves administration of a bone-seeking, alpha-particle emitting radionuclide 224Ra and its daughter radionuclide 212Pb solution containing chelator-labelled new and existing molecular ligands and tumour-associated monoclonal antibodies (mAb) as carriers for the daughter radionuclide. Pb-212 is a source of highly cytotoxic alpha particles via its decay to 212Bi daughter.
Contact information Asta Juzeniene, Scientist, Ph.D. Department of Radiation Biology, Institute for Cancer Research The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway Tel. +47 22 78 12 00, Fax +47 22 78 12 07
Christopoulos PF, Grigalavicius M, Corthay A, Berg K, Theodossiou TA(2021) Reactive Species from Two-Signal Activated Macrophages Interfere with Their Oxygen Consumption Measurements Antioxidants (Basel), 10(7) DOI 10.3390/antiox10071149, PubMed 34356382
Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland ØS, Juzeniene A(2021) Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer Int J Mol Sci, 22(9) DOI 10.3390/ijms22094815, PubMed 34062920
Li RG, Lindland K, Tonstad SK, Bønsdorff TB, Juzeniene A, Westrøm S, Larsen RH(2021) Improved Formulation of 224Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP Pharmaceutics, 13(5) DOI 10.3390/pharmaceutics13050634, PubMed 33946852